Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. - Test2 - elhamkhani - TriplyDB

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

http://www.wikidata.org/entity/Q33955200

about

Matricellular proteins: a sticky affair with cancers Loss of SPARC in bladder cancer enhances carcinogenesis and progression.SPARC overexpression suppresses radiation-induced HSP27 and induces the collapse of mitochondrial Δψ in neuroblastoma cells Secreted protein acidic and rich in cysteine (SPARC) suppresses angiogenesis by down-regulating the expression of VEGF and MMP-7 in gastric cancer.Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK.SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation The expression of SPARC in human intracranial aneurysms and its relationship with MMP-2/-9.The clinical impact of mean vessel size and solidity in breast carcinoma patients.Cooperative Cross-Talk between Neuroblastoma Subtypes Confers Resistance to Anaplastic Lymphoma Kinase Inhibition.The role of SPARC protein expression in the progress of gastric cancer.Notch signaling regulates tumor-induced angiogenesis in SPARC-overexpressed neuroblastoma SPARC expression by cerebral microvascular endothelial cells in vitro and its influence on blood-brain barrier properties SPARC overexpression combined with radiation retards angiogenesis by suppressing VEGF-A via miR‑410 in human neuroblastoma cells.Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model.Roles of SPARC in urothelial carcinogenesis, progression and metastasis.Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids.Microenvironment and tumor progression of melanoma: new therapeutic prospectives.The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease.Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation.Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1.Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells.Using a Classifier Fusion Strategy to Identify Anti-angiogenic Peptides SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression

P2860

Q21296660-5F079914-4053-4A57-A21C-1D8FE7E021C3 Q30422650-6D3625C9-D3C0-4D3D-95EE-9AFE2B2CC00F Q33751169-A65F7A60-1AA4-4B5E-BC73-A039F5F3B2F6 Q34408242-D5B97727-98BC-4865-B370-FC932F41B4CC Q34525997-A6E36CCF-F265-4403-A465-A21CBEE73BE3 Q34577489-450E9606-5753-4BE8-B3C1-71F4829791DF Q34629656-7AEC06FC-78C0-450C-8E13-E9432BAF5C13 Q35022553-44A03CE3-549B-4EF2-9A7D-7684E36106F9 Q35180335-7242F176-BE6B-4317-8935-F6D863A11BC1 Q35928814-DD61CB45-83A7-4688-B1A1-B767CD262BC8 Q36481114-5B134261-A967-4CA4-B624-BF64BD82B419 Q37223975-E7948965-7FEA-4B16-878F-3799AD37FC05 Q37252700-BC31C68E-34E4-4098-B41E-2679E8A72BDC Q37327668-B45BD590-6483-448B-9FE7-6A321C07F9F9 Q37687199-8533EE2E-A00F-4AAF-AABA-769FFD6A25E2 Q37718422-780A259B-D740-4516-8173-CD273D436F85 Q38049368-12B69E6C-F373-4196-B6B2-D6D090207F75 Q38985417-29B66A16-96D3-4D22-A26D-98BFCC2AA2B2 Q39391640-896BA7C0-ED9B-4572-BA18-F1F44BBEA7D3 Q39432147-69EE6445-423E-4839-A1B3-AF9480E36CF5 Q40153387-E07FFC87-3A57-4537-9A2C-42195D7EEC6A Q40854486-464D9C93-6483-46F7-BE59-B0470A9D5A71 Q58740632-8DB1400E-7B86-4894-867F-2BA8EFA5E9D8 Q59011501-B0A6245C-CF24-42BF-859D-80C4686615DA

P2860

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

http://www.wikidata.org/entity/Q33955200

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

@ast

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

@en

type

label

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

@ast

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

@en

prefLabel

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

@ast

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

@en

P1433

Q33955200-48368478-F526-4A34-BE27-5498CD4C5D4D

P1476

Q33955200-5FB3ABB7-2FB5-4F73-9FF9-AAB06577F4DA

P2093

Q33955200-00C682DF-6D82-4950-8C07-4892A405CE60

Q33955200-3C326600-47DC-4B7E-91FF-A300CD2A0F0E

Q33955200-AC148D18-1AB4-492A-948C-0B347C6FB561

Q33955200-ACDE68BE-DFAC-4D81-AB64-437D77B93132

Q33955200-C510F975-DBD1-4B4C-A173-440A29BDA869

Q33955200-CB57F0AD-7676-4C6D-9BF4-1F028141F76F

Q33955200-CFB0A8D5-20DD-4FCE-9A72-39144E2125E1

Q33955200-E8ABDC89-6DFF-4A10-B65B-035F5EDE6BA7

P2860

Q33955200-028F3C83-6A23-46BD-BAF3-2F092F232A47

Q33955200-03A7F986-0E47-4B54-8F7D-44698323FA50

Q33955200-05561B42-A3DA-4139-9203-5BABC89B15DE

Q33955200-0A48E2AA-F514-480B-BA8E-96E3B1B196B2

Q33955200-0AEE81EE-C3A8-4787-ABA0-F9761D772592

Q33955200-0C9BAA1A-C731-425A-BBC8-3BDBD68CC5D8

Q33955200-102AE970-85CF-46B8-9EA7-ED83595434E0

Q33955200-1C846CC4-5894-4C05-8306-FF11FAB58337

Q33955200-2C30B1F9-008F-462C-84B3-7D8FD5C8C9C4

Q33955200-2C4D2772-CEE3-42F6-952D-D41356C75CC0

P2888

Q33955200-E3C56624-6522-4509-8515-38F51DA610A8

P304

Q33955200-75539EE2-C3A5-4280-84EE-BFCF3C9ED98C

P31

Q33955200-D71B9D13-060F-4703-AF45-CC724009AF00

P356

Q33955200-DCCE019F-C602-4B50-92F1-1F90B039C716

P478

Q33955200-2906ACCF-815E-4E63-A35B-571CA6F54C06

P50

Q33955200-B1B5578E-DCDF-4117-89FA-9875F5A7500A

P577

Q33955200-CBC14EFA-41F7-4D23-9DC3-5E07F60B189F

P5875

Q33955200-9BA10FA3-891C-4CED-935F-1CE72B59109B

P6179

Q33955200-F0ED7DE3-E884-4035-97B2-387D61D63E4A

P698

Q33955200-6CD33067-9D66-4EB6-8898-8C8BFF6F242D

P932

Q33955200-21C03430-231B-414B-80D2-C3ED1F7F3C46

P356

1476-4598-9-138

P1433

Molecular Cancer

P1476

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

@en

P2093

Alexandre Chlenski

http://www.w3.org/2001/XMLSchema#string

Helen R Salwen

http://www.w3.org/2001/XMLSchema#string

Jared A Spitz

http://www.w3.org/2001/XMLSchema#string

Lisa J Guerrero

http://www.w3.org/2001/XMLSchema#string

Payton T Leonhardt

http://www.w3.org/2001/XMLSchema#string

Qiwei Yang

http://www.w3.org/2001/XMLSchema#string

Radhika Peddinti

http://www.w3.org/2001/XMLSchema#string

Yufeng Tian

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma

Distinct antitumor properties of a type IV collagen domain derived from basement membrane

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture

Distribution of osteonectin mRNA and protein during human embryonic and fetal development

SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth.

Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma.

P2888

1476-4598-9-138

P304

138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-9-138

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44651291

http://www.w3.org/2001/XMLSchema#string

P6179

1040287637

http://www.w3.org/2001/XMLSchema#string

P698

20525313

http://www.w3.org/2001/XMLSchema#string

P932

2895596

http://www.w3.org/2001/XMLSchema#string